Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in children with SCD: a V114-023 (PNEU-SICKLE) study

Autor: Quinn, Charles T., Wiedmann, Richard T. ^∗, Jarovsky, Daniel, Lopez-Medina, Eduardo, Rodriguez, Hilze M., Papa, Melanie, Boggio, Gordana, Shou, Qiong, Dagan, Ron, Richmond, Peter, Feemster, Kristen, McFetridge, Richard, Tamms, Gretchen, Lupinacci, Robert, Musey, Luwy, Bickham, Kara

Publikováno v: In Blood Advances 14 February 2023 7(3):414-421

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience

Autor: Lievano, Fabio, Galea, Susan A., Thornton, Michele, Wiedmann, Richard T., Manoff, Susan B., Tran, Trung N., Amin, Manisha A., Seminack, Margaret M., Vagie, Kristen A., Dana, Adrian, Plotkin, Stanley A.

Publikováno v: In Vaccine 6 November 2012 30(48):6918-6926

Effects of Isoproterenol on Twitch Contraction of Wild Type and Phospholamban-deficient Murine Ventricular Myocardium

Autor: Pan, Bo-Sheng, Hannon, James D., Wiedmann, Richard, Potter, James D., Kranias, Evangelia G., Shen, You-Tang, Johnson, Jr., Robert G., Housmans, Philippe R.

Publikováno v: In Journal of Molecular and Cellular Cardiology January 1999 31(1):159-166

Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study

Autor: Manns, Michael P, Gane, Edward, Rodriguez-Torres, Maribel, Stoehr, Albrecht, Yeh, Chau-Ting, Marcellin, Patrick, Wiedmann, Richard T, Hwang, Peggy M, Caro, Luzelena, Barnard, Richard J O, Lee, Andrew W, Negro, Francesco

Publikováno v: Hepatology, Vol. 56, No 3 (2012) pp. 884-93
Manns, M P, Gane, E, Rodriguez-Torres, M, Stoehr, A, Yeh, C-T, Marcellin, P, Wiedmann, R T, Hwang, P M, Caro, L, Barnard, R J O, Lee, A W, MK-7009 Protocol 007 Study Group & Pedersen, C 2012, ' Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C : a randomized phase II study ', Hepatology (Baltimore, Md.), vol. 56, no. 3, pp. 884-893 . https://doi.org/10.1002/hep.25743

Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. The aim of the present phase II study was to examine virologic response rates with vaniprevir in combination with pegylated interferon alpha-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bd1323aa36d04f601a708f589679fc1
https://archive-ouverte.unige.ch/unige:27062